Director, Commercial Strategy & New Product Planning

The Director, Commercial Strategy & New Product Planning will lead and support a wide range of strategic and operational initiatives across MBX's portfolio. This individual will help shape commercialization strategy for canvuparatide while also helping define the future direction of our obesity and metabolic disease pipeline. The ideal candidate combines strong analytical and strategic capabilities with a willingness to roll up their sleeves and execute. This role is well suited for individuals coming from biopharmaceutical marketing, commercial strategy, business analytics, or leading life sciences consulting firms who are excited to build, influence decisions, and grow alongside an emerging organization.

Help define long-term commercial strategy across MBX's portfolio

Evaluate market opportunities, competitive dynamics, and evolving standards of care

Support portfolio prioritization and investment decisions

Develop commercial assessments for new indications, lifecycle opportunities, and business development initiatives

Partner closely with R&D and clinical teams to ensure commercial considerations are incorporated into development plans

Support launch planning and commercialization activities for canvuparatide

Identify key market opportunities, barriers to adoption, and launch risks

Develop launch assumptions and readiness plans across key functional areas

Help establish foundational commercial capabilities and processes as MBX prepares for commercialization

Lead market research initiatives with physicians, patients, payers, and other stakeholders

Translate market insights into actionable strategic recommendations

Monitor competitive developments and emerging market trends

Develop deep understanding of customer needs, treatment journeys, and market dynamics

Support development of product positioning, value propositions, and messaging frameworks

Contribute to brand strategy and commercialization planning

Develop and refine Target Product Profiles (TPPs) and commercial product profiles

Assess differentiation opportunities and competitive positioning across the portfolio

Support development and refinement of demand forecasts and commercial models

Evaluate market sizing, patient flow, and adoption assumptions

Develop strategic analyses to inform investment decisions and resource allocation

Prepare presentations and recommendations for executive leadership and Board discussions

Partner closely with Clinical Development, Medical Affairs, Regulatory, Market Access, Finance, Investor Relations, and Business Development

Lead cross-functional projects and strategic workstreams

Manage external agencies, consultants, and research partners as needed

Serve as a key commercial representative on cross-functional teams

Bachelor's degree required; advanced degree preferred (MBA, MPH, PharmD, PhD, or related field)

8+ years of relevant experience in biotechnology, pharmaceuticals, healthcare consulting, or related fields

Experience in commercial strategy, marketing, new product planning, forecasting, market research, analytics, or consulting

Strong analytical, strategic thinking, and problem-solving skills

Excellent communication and presentation abilities

Ability to operate effectively in a fast-paced, entrepreneurial environment

You will be expected to travel periodically, based on business needs, including attending Together Weeks, Together Days, and functional meetings as requested by the Company. This role is expected to be on-site an average of three days per week, unless otherwise requested.

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.